Cytotoxicity of Aβ1-42, RAGE23-54, and an Aβ-RAGE complex in PC-12 cells

Current Alzheimer Research

Volumn 4, Issue 5, 2007, Pages 581-586

  Mruthinti, Shyamala ^a,b   Capito, Nicholas ^a   Sood, Ajay ^b   Buccafusco, Jerry J ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Amyloid; Cultured cells; Glycation end products; Mitochondrial function; Protein complexes

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR 23-54; AMYLOID BETA PROTEIN[1-42]; UNCLASSIFIED DRUG; ADVANCED GLYCATION END PRODUCT; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL CELL; BINDING AFFINITY; BLOOD SAMPLING; CASE REPORT; CELL STRAIN; CELL VIABILITY; COMPLEX FORMATION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; MOLECULAR WEIGHT; NEUROTOXICITY; NONHUMAN; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN BINDING; RAT; ANALYSIS OF VARIANCE; ANIMAL; ARTICLE; CELL SURVIVAL; CHEMISTRY; DRUG COMBINATION; DRUG EFFECT; METABOLISM; TIME;

AMYLOID BETA-PROTEIN; ANALYSIS OF VARIANCE; ANIMALS; CELL SURVIVAL; DRUG COMBINATIONS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; PC12 CELLS; PEPTIDE FRAGMENTS; RATS; TIME FACTORS;

EID: 37049036195     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720507783018325     Document Type: Conference Paper

References (22)

1. Puzzo D and Arancio O. Fibrillar β-amyloid impairs the late phase of long term potentiation. Current Alzheimer Res 3: 179-183 (2006).
2. Monnier VM, Kohn RR and Cerami A. Accelerated age related browning of human in diabetes mellitus. Proc Natl Acad Sci USA 81: 583-587 (1984).
3. Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Yan SD, et al. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274: 31740-31749 (1999).
4. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan Y-CE, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267: 14998-15004 (1992).
5. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382: 685-691 (1996).
6. Yan SD, Zhu H, Fu J, Yan SF, Roher A, Tourtellotte WW, et al. Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc National Acad Sci USA 94: 5296-5301 (1997).
7. Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM, et al. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol 171: 29-45 (2001).
8. Arancio O, Zhang HP, Chen X, Lin C, Trinchese F, Puzzo D, et al. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J 23: 4096-105 (2004).
9. Yann V and Penke B. Binding sites of amyloid β-peptide in cell plasma membrane and implications for Alzheimer's disease. Current Protein Pept Sci 5: 19-31(2004).
10. Sasaki N, Toki S, Chowei H, Saito T, Nakano N, Hayashi Y, et al. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res 888: 256-262 (2001).
11. Mruthinti S, Buccafusco JJ, Hill WD, Waller JL, Jackson TW, Zamrini EY, et al. Autoimmunity in Alzheimer's disease: Increased levels of circulating IgGs binding Aβ and RAGE peptides. Neurobiol Aging 25: 1023-1032 (2004).
12. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155: 853-62 (1999).
13. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, et al. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA 283: 1571-1577 (2000).
14. Kuo Y-M, Emmerling MR, Lampert HC, Hempelman SR, Kokjohn TA, Woods AS, et al. High levels of circulating Aβ42 are sequestered by plasma proteins in Alzheimer's disease. Biochem Biophys Res Comm 257: 787-791 (1999).
15. Matsunaga N, Anan I, Forsgren S, Nagai R, Rosenberg P, Horiuchi S, et al. Advanced glycation end products (AGE) and the receptor for AGE are present in gastrointestinal tract of familial amyloidotic polyneuropathy patients but do not induce NF-kappaB activation. Acta Neuropathologica 104: 441-447 (2002).
16. Chaney MO, Stine WB, Kokjohn TA, Kuo YM, Esh C, Rahman A, et al. RAGE and amyloid beta interactions: atomic force microscopy and molecular modeling. Biochim Biophys Acta. 1741: 199-205 (2005).
17. Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE, et al. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding disease. J Biol Chem 279: 46363-46366 (2004).
18. Deshpande A, Mina E, Glabe C, and Busciglio J. Different conformations of amyloid β induce neurotoxicity by distinct mechanims in human cortical neurons. J Neurosci 26: 6011-6018 (2006).
19. Mruthinti S, Hill WD, Swamy-Mruthinti S and Buccafusco JJ. Relationship between the induction of RAGE cell-surface antigen and the expression of amyloid binding sites. J Mol Neurosci 20: 17-26 (2003).
20. Lue LF, Yan SD, Stern DM, andWalker DG. Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease. Curr Drug Targets - CNS Neurolog Disor 4: 249-66 (2005).
21. Schmitt HP. epsilon-Glycation, APP and Abeta in ageing and Alzheimer disease: a hypothesis. Medical Hypotheses 66: 898-906 (2006).
22. Onyango IG, Tuttle JB and Bennett JP Jr. Altered intracellular signaling and reduced viability of Alzheimer's disease neuronal cybrids is reproduced by beta-amyloid peptide acting through receptor for advanced glycation end products (RAGE). Mol Cell Neurosci 29: 333-343 (2005).